CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma
A single infusion of BCMA-directed CAR-T cells produced responses in 97% of patients whose myeloma had failed a median of six prior lines, with two-thirds reaching stringent complete response.
CARTITUDE-1 was a phase 1b/2 single-arm study of ciltacabtagene autoleucel (cilta-cel), a CAR-T with two BCMA-binding domains, in 97 patients with relapsed or refractory multiple myeloma exposed to a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 antibody (median six prior lines, 88% triple-class refractory). The overall response rate was 97%, with stringent complete response in 67%; 12-month PFS was 77% and OS 89%. Cytokine release syndrome occurred in 95% (grade 3-4 in about 4%) and neurotoxicity in about 21%, including a small number of delayed movement and neurocognitive events. Long-term follow-up showed roughly a third of patients progression-free at five years without further therapy, unprecedented in this population.
- 97 patients infused; median 6 prior lines; 88% triple-class refractory.
- Overall response 97%; stringent complete response 67%; MRD-negativity in most evaluable responders.
- 12-month PFS 77%, OS 89%; median PFS about 35 months in later follow-up; about a third progression-free at 5 years.
- CRS in 95% (grade 3-4 about 4%); ICANS 17%; delayed movement/neurocognitive syndrome in a minority.
- Median time to CRS onset was 7 days, later than with CD19 CAR-Ts, enabling outpatient monitoring strategies.
CARTITUDE-1 showed that a single CAR-T infusion can put late-stage myeloma into deep, multi-year remission, leading to FDA approval of cilta-cel in 2022 for heavily pretreated disease. It set the efficacy bar for BCMA-directed therapy and motivated moving CAR-T earlier (CARTITUDE-4). Late neurological toxicity and secondary malignancies remain the safety questions.
- Single-arm trial in fit, selected patients; no randomised comparator.
- Manufacturing failures and bridging deaths are not captured in infused-patient analyses.
- Delayed parkinsonism-like neurotoxicity and rare second primary malignancies (including T-cell lymphoma) emerged with follow-up.
- Access limited by manufacturing slots and cost.